About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2021№8
Clinical risk factors for endometrial...

Clinical risk factors for endometrial hyperplastic processes in perimenopausal women

DOI
https://dx.doi.org/10.18565/aig.2021.8.32-38

Huseynova R.G., Ordiyants I.М., Persidskaya A.A.

Peoples’ Friendship University of Russia, Ministry of Education and Science of the Russian Federation, Moscow, Russian Federation
Currently, cancers are of leading importance in the structure of mortality worldwide. Among the female population, malignant endometrial neoplasms occupy the second place in their incidence. Endometrial hyperplastic processes are presently considered to be precursors of malignant transformation, which is especially relevant in able-bodied women. There is evidence that the incidence of endometrial hyperplasia (EH) varies from 10 to 55% and reaches its maximum in the population of perimenopausal women. The paper analyzes an update on clinical risk factors for endometrial hyperplasia in perimenopausal women. Among the most significant background conditions, there are diabetes mellitus, obesity, factors of gynecological history and hormone therapy, including that for malignant breast neoplasms. Changes in the expression of estrogen and progesterone receptors play an important role in the development of pathological effects and their relationship to the development of hyperplastic processes.
Conclusion. The use of molecular genetic testing in the study of the course and progression of HE and malignant transformation makes it possible to explain the mechanisms of the effects of risk factors and to clarify their significance for assessing the development of the disease. To select therapeutic tactics and to predict drug therapy success, it seems promising to evaluate the receptor status of patients with HE.

Keywords

endometrium
endometrial cancer
endometrial hyperplasia
Full text (in Russian)

References

  1. Петрова Г.В., Старинский В.В., Грецова О.П., Шахзадова А.О., Самсонов Ю.В. Состояние онкологической помощи населению России в 2017 г. по данным федерального статистического наблюдения. Онкология. Журнал им. П.А.Герцена. 2019; 8(1): 32-40. [Petrova G.V., Starinsky V.V., Gretsova O.P., Shakhzadova A.O., Samsonov Yu.V. Cancer care to the population of Russia in 2017 according to the data of federal statistical observation. 2019; 8(1): 32-40. (in Russian)].
  2. Arem H., Irwin M.L. Obesity and endometrial cancer survival: A systematic review. Int. J. Obes. 2013; 37(5): 634-9. https://dx.doi.org/10.1038/ijo.2012.94.
  3. Cramer D.W. The epidemiology of endometrial and ovarian cancer. Hematol. Oncol. Clin. North Am. 2012; 26(1): 1-12. https://dx.doi.org/10.1016/j.hoc.2011.10.009.
  4. Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A.B. et al. Endometrial cancer: a review and current management strategies: Part II. Gynecol. Oncol. 2014; 134(2): 393-402. https://dx.doi.org/10.1016/j.ygyno.2014.06.003.
  5. Siegel R.L. Miller K.D., Jemal A. Cancer statistics, 2018. CA: Cancer J. Clin. 2018; 68(1): 7-30. https://dx.doi.org/10.3322/caac.21442.
  6. Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов. Онкогинекология. 2018; 27(3): 64-78. [Aksel E.M., Vinogradova N.N. Statistics of malignant neoplasms of female reproductive organs. Oncogynecology. 2018; 27(3): 64-78. (in Russian)]
  7. Киселев В.И., Сидорова И.С., Унанян А.Л., Муйжнек Е.Л. Гиперпластические процессы органов женской репродуктивной системы: теория и практика. М.: Медпрактика-М; 2011. 467c. [Kiselev V.I., Sidorova I.S., Unanyan A.L., Muizhnek E.L. Hyperplastic processes of the organs of the female reproductive system: theory and practice. M.: Medpraktika-M; 2011.467p. (in Russian)].
  8. Singh G., Puckett Y. Endometrial hyperplasia. StatPearls Publishing; 2020.
  9. Jeong J.Y., Hwang S.O., Lee B., Kim K., Kim Y.B., Park S.H., Choi H.Y. Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study. PLoS One. 2020; 15(12): e0243064. https://dx.doi.org/10.1371/journal.pone.0243064.
  10. Cullen T.S. Cancer of the uterus: its pathology, symptomatology, diagnosis, and treatment. New York: D. Appleton-Century Company; 1900.
  11. Gibson D.A., Saunders P.T. Estrogen dependent signaling in reproductive tissues – A role for estrogen receptors and estrogen related receptors. Mol. Cell. Endocrinol. 2012; 348(2): 361-72. https://dx.doi.org/10.1016/j.mce.2011.09.026.
  12. Bircan S., Ensari A., Ozturk S., Erdogan N., Dundar I., Ortac F. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol. Oncol. Res. 2005; 11(1): 32-9.
  13. Uchikawa J., Shiozawa T., Shih H.C., Miyamoto T., Feng Y.Z., Kashima H. et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer. 2003; 98(10): 2207-13. https://dx.doi.org/10.1002/cncr.11760.
  14. Hu K., Zhong G., He F. Expression of estrogen receptors ERα and ERβ in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer. 2005; 15(3): 537-41. https://dx.doi.org/10.1111/j.1525-1438.2005.15321.x.
  15. Chakravarty D., Srinivasan R., Ghosh S., Rajwanshi A., Gopalan S. Estrogen receptor beta (ERβ) in endometrial simple hyperplasia and endometrioid carcinoma. Appl. Immunohistochem. Mol. Morphol. 2008; 16(6): 535-42. https://dx.doi.org/10.1097/PAI.0b013e31816755a9.
  16. Пономаренко И.В., Полоников А.В., Чурносов М.И. Ассоциация полиморфизма rs4986938 гена ESR2 с развитием гиперплазии эндометрия. Акушерство и гинекология. 2019; 4: 66-72. [Ponomarenko I.V., Polonikov A.V., Churnosov M. I. Association of Esr2 rs4986938 polymorphism with the development of endometrial hyperplasia. Obstetrics and Gynecology. 2019; 1: 66-72. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.4.66-72.
  17. Pieczyńska B., Wojtylak S., Zawrocki A., Biernat W. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray. Pol. J. Pathol. 2011; 62(3):133-8.
  18. Савельева Г.М., Бреусенко В.Г., Карева Е.Н., Ивановская Т.Н., Кочина Н.А., Гуторова Д.С. Изучение роли экспрессии генов рецепторов эстрогенов и прогестерона в возникновении пролиферативных процессов в эндометрии для решения вопроса о тактике ведения больных с указанными патологическими изменениями эндометрия. Российский вестник акушера-гинеколога. 2018; 18(6): 17-24. [Savelyeva G.M., Breusenko V.G., Kareva E.N., Ivanovskaya T.N., Kochina N.A., Gutorova D.S. Investigation of the role of estrogen receptor and progesterone receptor gene expressions in the occurrence of endometrial proliferative processes to address the issue of management tactics for patients with these pathological changes in the endometrium. Russian bulletin of obsheter-gynecologist. 2018; 18(6): 17-24. (in Russian)]. doi:10.17116/rosakush20181806117.
  19. Orejuela F.J., Ramondetta L.M., Smith J., Brown J., Lemos L.B., Li Y., Hollier L.M. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol. Oncol. 2005; 97(2): 483-8. https://dx.doi.org/10.1016/j.ygyno.2005.02.010.
  20. Faloppa C.C., Baiocchi G., Cunha I.W., Fregnani J.H.T.G., Osorio C.A.B.T., Fukazawa E.M. et al. NF-κB and COX-2 expression in nonmalignant endometrial lesions and cancer. Am. J. Clin. Pathol. 2014; 141(2): 196-203. https://dx.doi.org/10.1309/AJCPV7U7PGHOWEQG.
  21. Erkanli S., Bolat F., Kayaselcuk F., Demirhan B., Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol. Oncol. 2007; 104(2): 320-5. https://dx.doi.org/10.1016/j.ygyno.2006.08.044.
  22. Ma X., Hui Y., Lin L., Wu Y., Zhang X., Liu P. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak. J. Med. Sci. 2015; 31(2): 280-4. https://dx.doi.org/10.12669/pjms.312.6604.
  23. Клинышкова Т.В., Тучанинов Д.В., Фролова Н.Б. Клинико-эпидемиологические аспекты рака тела матки с позиции профилактики рецидивирования гиперплазии эндометрия. Акушерство и гинекология. 2020; 1: 135-40. [Klinyshkova T.V., Turchaninov D.V., Frolova Natalia B. Clinical and epidemiological aspects of corpus uteri cancer in the context of prevention of recurrent endometrial hyperplasia. Obstetrics and Gynecology. 2020; 1: 135-40. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.1.135-140.
  24. Пономаренко И.В., Полоников А.В., Чурносов М.И. Гиперпластические процессы эндометрия: этиопатогенез, факторы риска, полиморфизм генов-кандидатов. Акушерство и гинекология. 2019; 1: 13-8. [Ponomarenko I.V., Polonikov A.V., Churnosov M.I. Endometrial hyperplastic processes: etiopathogenesis, risk factors, polymorphism of candidate genes. Obstetrics and Gynecology. 2019; 1: 13-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.1.13-18.
  25. Чернуха Г.Е., Асатурова А.В., Иванов И.А., Думановская М.Р. Структура патологии эндометрия в различные возрастные периоды. Акушерство и гинекология. 2018; 8: 129-34. [Chernukha G.E., Asaturova A.V., Ivanov I.A., Dumanovskaya M.R. Endometrial lesion's pattern in different age groups. Obstetrics and Gynecology. 2018; 8: 129-34. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.8.129-134.
  26. Raglan O., Kalliala I., Markozannes G., Cividini S., Gunter M.J., Nautiyal J. et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int. J. Cancer. 2019; 145(7): 1719-30. https://dx.doi.org/10.1002/ijc.31961.
  27. Wu Q.J., Li Y.Y., Tu C., Zhu J., Qian K.Q., Feng T.B. et al. Parity and endometrial cancer risk: A meta-analysis of epidemiological studies. Sci. Rep. 2015; 5: 14243. https://dx.doi.org/10.1038/srep14243.
  28. Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000; 2(5): 335-44. https://dx.doi.org/10.1186/bcr78.
  29. Fleming C.A., Heneghan H.M., O’Brien D., McCartan D.P., McDermott E.W., Prichard R.S. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg. 2018; 105(9): 1098-106. https://dx.doi.org/10.1002/bjs.10899.
  30. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J. Natl. Cancer Inst. 2001; 93(6): 456-62. https://dx.doi.org/10.1093/jnci/93.6.456.
  31. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805-16. https://dx.doi.org/10.1016/S0140-6736(12)61963-1.
  32. Zhang K., Luo Y., Dai H., Deng Z. Effects of bariatric surgery on cancer risk: evidence from meta-analysis. Obes. Surg. 2020; 30(4): 1265-72. https://dx.doi.org/10.1007/s11695-019-04368-4.
  33. Giannella L., Cerami L.B., Setti T., Bergamini E., Boselli F. Prediction of endometrial hyperplasia and cancer among premenopausal women with abnormal uterine bleeding. Biomed Res. Int. 2019: 8598152. https://dx.doi.org/10.1155/2019/8598152.
  34. Kacalska-Janssen O., Rajtar-Ciosek A., Zmaczyński A., Wyroba J., Milewicz T., Krzyczkowska-Sendrakowska M., Krzysiek J. Markers of insulin resistance in perimenopausal women with endometrial pathology. Ginekol. Pol. 2013; 84(11): 922-9. https://dx.doi.org/10.17772/gp/1661.
  35. Epplein M., Reed S.D., Voigt L.F., Newton K.M., Holt V.L., Weiss N.S. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am. J. Epidemiol. 2008; 168(6): 563-70. https://dx.doi.org/10.1093/aje/kwn168.
  36. Бабурин Д.В., Унанян А.Л., Сидорова И.С., Кудрина И.А., Ищенко А.И. Гиперпластические процессы эндометрия у женщин перименопаузального возраста: клинические аспекты проблемы. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2017; 4(4): 201-7. [Baburin D.V., Unanyan A.L., Sidorova I.S., Kudrina I.A., Ishchenko A.I. Hyperplastic processes of endometrium in women of perimenopausal age: clinical aspects of the problem. V.F. Snegirev Archives of Obstetrics and Gynecology. 2017; 4 (4): 201-7. (in Russian)].
  37. Колесова Т.Е., Кoбаидзе Е.Г., Статных Н.В., Завьялова Ю.А. Значение оценки факторов риска в диагностике рака эндометрия. В кн.: Материалы XXI Международной научной конференции "Онкология – XXI век", VII Итало-Российской научной конференции по онкологии и эндокринной хирургии, XXI Международной научной конференции "Здоровье нации - XXI век". Пермь: Книжный формат; 2017: 123-7. [Kolesova T.E., Kobaidze E.G., Statnykh N.V., Zavyalova Y.A. Significance of risk factors evaluation in diagnosis of endometrial carcinoma. Oncology – XXI century. 2017: 123-7. (in Russian)].
  38. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A. et al. Diabetes and cancer: A consensus report. CA: Cancer J. Clin. 2010; 60(4): 207-21. https://dx.doi.org/10.3322/caac.20078.
  39. Tsilidis K.K. Type 2 diabetes and cancer: Umbrella review of meta-analyses of observationlal studies. BMJ. 2015; 350: g7607. https://dx.doi.org/10.1136/bmj.g7607.
  40. Nead K.T., Sharp S.J., Thompson D.J., Painter J.N., Savage D.B., Semple R.K. et al. Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J. Natl. Cancer Inst. 2015; 107(9): djv178. https://dx.doi.org/10.1093/jnci/djv178.
  41. Raffone A., Travaglino A., Saccone G., Maio A.D., Mollo A., Mascolo M. et al. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol. Endocrinol. 2019; 35(11): 932-7. https://dx.doi.org/10.1080/09513590.2019.1624716.
  42. Goncharenko V.M., Beniuk V.A., Kalenska O.V., Demchenko O.M., Spivak M.Y., Bubnov R.V. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013; 4(1): 24. https://dx.doi.org/10.1186/1878-5085-4-24.
  43. Ponomarenko I., Reshetnikov E., Polonikov A., Sorokina I., Yermachenko A., Dvornyk V., Churnosov M. Candidate genes for age at menarche are associated with endometrial hyperplasia. Gene. 2020; 757: 144933. https://dx.doi.org/10.1016/j.gene.2020.144933.
  44. Niskakoski A., Pasanen A., Porkka N., Eldfors S., Lassus H., Renkonen-Sinisalo L. et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecol. Oncol. 2018; 150(1): 92-8. https://dx.doi.org/10.1016/j.ygyno.2018.04.566.

Received 15.02.2021

Accepted 20.04.2021

About the Authors

Roya G. Huseynova, postgraduate student of the Department of Obstetrics and Gynecology, Medical Institute, RUDN University. Tel.: +7(966)008-77-44.
E-mail: royka.isayeva@mail.ru. ORCID: 0000-0003-4164-8295. 117198, Russia, Moscow, Miklukho-Maklaya str., 8.
Irina M. Ordiyants, Dr. Med. Sci., Professor of the Department of Obstetrics and Gynecology, Medical Institute, RUDN University. E-mail: ordiyantc@mail.ru.
SPIN code: 9229-0029, AuthorID: 611533, ORCID: 0000-0001-5882-9995. 117198, Russia, Moscow, Miklukho-Maklaya str., 8.
Anastasia A. Persidskaya, postgraduate student of the Department of Obstetrics and Gynecology, Medical Institute, RUDN University. E-mail: yamurzinanastya@mail.ru. ORCID: 0000-0002-0774-2715. 117198, Russia, Moscow, Miklukho-Maklaya str., 8.

For citation: Huseynova R.G., Ordiyants I.М., Persidskaya A.A. Clinical risk factors for endometrial hyperplastic processes in perimenopausal women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2021; 8: 32-38 (in Russian)
https://dx.doi.org/10.18565/aig.2021.8.32-38

Similar Articles

№5 / 2024
Yarmolinskaya M.I., Koloshkina А.V.
Tissue-selective estrogen regulation capabilities in postmenopausal women
№10 / 2024
Levakov S.A., Gromova T.A., Gvazava E.N.
The potential role of the nervous system in endometrial cancer and endometrial hyperplasia as one of the risk factors for neotransformation
№3 / 2023
Marinkin I.O., Shpagina L.A., Lisova E.S., Kotova O.S., Kuznetsova G.V., Loktin E.M., Karmanovskaya S.A.
Endometrial hyperplasia in women with comorbid obesity working in contact with organic solvents
№11 / 2023
Frolova Yu.S., Elgina S.I.
Early diagnosis of endometrial hyperplasia based on clinical and anamnestic factors
№1 / 2023
Krasnopolskaya K.V., Novikova O.V., Isakova K.M., Shostenko L.V., Rau D.I., Shishkina A.V.
Feasibility of preimplantation genetic testing for aneuploidy in patients undergoing in vitro fertilization after conservative treatment of atypical hyperplasia and early endometrial cancer
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.